Javier Gilbert-Jaramillo

Javier Gilbert-Jaramillo

Auto-generated profile, based on publicly available information

Javier Gilbert-Jaramillo

Department of Psychiatry, Harvard Medical School, Belmont, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2020 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
JHJiangdong Huo
Jiangdong Huo
ABAudrey Le Bas
Audrey Le Bas
RRReinis R. Ruza
Reinis R. Ruza
HDHelen M. E. Duyvesteyn
Helen M. E. Duyvesteyn
HMHalina Mikolajek
Halina Mikolajek
JNJames H Naismith
James H Naismith
An amendment to this paper has been published and can be accessed via a link at the top of the paper.

1 April 2021 in Cell
Verified
Journal Article
Open access
WDWanwisa Dejnirattisai
Wanwisa Dejnirattisai
DZDaming Zhou
Daming Zhou
HGHelen M. Ginn
Helen M. Ginn
HDHelen M.E. Duyvesteyn
Helen M.E. Duyvesteyn
PSPiyada Supasa
Piyada Supasa
GSGavin R. Screaton
Gavin R. Screaton
Antibodies are crucial to immune protection against SARS-CoV-2, with some in emergency use as therapeutics. Here, we identify 377 human monoclonal antibodies (mAbs) recognizing the virus spike and focus mainly on 80 that bind the receptor binding domain (RBD). We devise a competition data-driven method to map RBD binding sites. We find that although antibody binding sites are widely dispersed, neutralizing antibody binding is focused, with nearly all highly inhibitory mAbs (IC50 < 0.1 μg/mL) blocking receptor interaction, except for one that binds a unique epitope in the N-terminal domain. Many of these neutralizing mAbs use public V-genes and are close to germline. We dissect the structural basis of recognition for this large panel of antibodies through X-ray crystallography and cryoelectron microscopy of 19 Fab-antigen structures. We find novel binding modes for some potently inhibitory antibodies and demonstrate that strongly neutralizing mAbs protect, prophylactically or therapeutically, in animal models.

31 July 2020 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
DZDaming Zhou
Daming Zhou
HDHelen M. E. Duyvesteyn
Helen M. E. Duyvesteyn
CCCheng-Pin Chen
Cheng-Pin Chen
CHChung-Guei Huang
Chung-Guei Huang
TCTing-Hua Chen
Ting-Hua Chen
KHKuan-Ying A. Huang
Kuan-Ying A. Huang
The COVID-19 pandemic has had an unprecedented health and economic impact and there are currently no approved therapies. We have isolated an antibody, EY6A, from an individual convalescing from COVID-19 and have shown that it neutralizes SARS-CoV-2 and cross-reacts with SARS-CoV-1. EY6A Fab binds the receptor binding domain (RBD) of the viral spike glycoprotein tightly (KD of 2 nM), and a 2.6-Å-resolution crystal structure of an RBD–EY6A Fab complex identifies the highly conserved epitope, away from the ACE2 receptor binding site. Residues within this footprint are key to stabilizing the pre-fusion spike. Cryo-EM analyses of the pre-fusion spike incubated with EY6A Fab reveal a complex of the intact spike trimer with three Fabs bound and two further multimeric forms comprising the destabilized spike attached to Fab. EY6A binds what is probably a major neutralizing epitope, making it a candidate therapeutic for COVID-19.

7 November 2017 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
RSRoberto Simone
Roberto Simone
RBRubika Balendra
Rubika Balendra
TMThomas G Moens
Thomas G Moens
EPElisavet Preza
Elisavet Preza
KWKatherine M Wilson
Katherine M Wilson
AIAdrian M Isaacs
Adrian M Isaacs
Intronic GGGGCC repeat expansions in C9orf72 are the most common known cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), which are characterised by degeneration of cortical and motor neurons, respectively. Repeat expansions have been proposed to cause disease by both the repeat RNA forming foci that sequester RNA‐binding proteins and through toxic dipeptide repeat proteins generated by repeat‐associated non‐ATG translation. GGGGCC repeat RNA folds into a G‐quadruplex secondary structure, and we investigated whether targeting this structure is a potential therapeutic strategy. We performed a screen that identified three structurally related small molecules that specifically stabilise GGGGCC repeat G‐quadruplex RNA. We investigated their effect in C9orf72 patient iPSC‐derived motor and cortical neurons and show that they significantly reduce RNA foci burden and the levels of dipeptide repeat proteins. Furthermore, they also reduce dipeptide repeat proteins and improve survival in vivo, in GGGGCC repeat‐expressing Drosophila. Therefore, small molecules that target GGGGCC repeat G‐quadruplexes can ameliorate the two key pathologies associated with C9orf72 FTD/ALS. These data provide proof of principle that targeting GGGGCC repeat G‐quadruplexes has therapeutic potential. Synopsis Small molecules targeting G‐quadruplex GGGGCC repeat RNA are effective at ameliorating disease phenotypes in C9orf72 patient neurons, and in vivo phenotypes in C9orf72 flies. Therefore, targeting expanded GGGGCC RNA could be an effective therapeutic strategy for C9orf72 ALS and FTD. FRET based screen identifies small molecules that specifically bind to C9orf72 repeat RNA G‐quadruplexes. Small molecules reduce RNA foci and dipeptide repeat proteins (DPRs) in C9orf72 patient neurons. G‐quadruplex GGGGCC binding small molecule improves survival and reduces levels of the toxic DPR poly‐GR in C9orf72 flies. Provides proof of principle for targeting GGGGCC RNA G‐quadruplexes in C9orf72 FTD/ALS.

17 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
DSDonal Skelly
Donal Skelly
AHAdam C. Harding
Adam C. Harding
JGJavier Gilbert-Jaramillo
Javier Gilbert-Jaramillo
MKMichael L. Knight
Michael L. Knight
Stephanie LongetStephanie Longet
Stephanie Longet
WJWilliam S. James
William S. James
The extent to which immune responses to natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and immunization with vaccines protect against variants of concern (VOC) is of increasing importance. Accordingly, here we analyse antibodies and T cells of a recently vaccinated, UK cohort, alongside those recovering from natural infection in early 2020. We show that neutralization of the VOC compared to a reference isolate of the original circulating lineage, B, is reduced: more profoundly against B.1.351 than for B.1.1.7, and in responses to infection or a single dose of vaccine than to a second dose of vaccine. Importantly, high magnitude T cell responses are generated after two vaccine doses, with the majority of the T cell response directed against epitopes that are conserved between the prototype isolate B and the VOC. Vaccination is required to generate high potency immune responses to protect against these and other emergent variants.

12 October 2020 in Wellcome Open Research
Verified
Journal Article
Open access
PDF file
MAMonique I. Andersson
Monique I. Andersson
CACarolina V. Arancibia-Carcamo
Carolina V. Arancibia-Carcamo
KAKathryn Auckland
Kathryn Auckland
JBJ. Kenneth Baillie
J. Kenneth Baillie
EBEleanor Barnes
Eleanor Barnes
MZMaria Zambon
Maria Zambon
Background: Laboratory diagnosis of SARS-CoV-2 infection (the cause of COVID-19) uses PCR to detect viral RNA (vRNA) in respiratory samples. SARS-CoV-2 RNA has also been detected in other sample types, but there is limited understanding of the clinical or laboratory significance of its detection in blood. Methods: We undertook a systematic literature review to assimilate the evidence for the frequency of vRNA in blood, and to identify associated clinical characteristics. We performed RT-PCR in serum samples from a UK clinical cohort of acute and convalescent COVID-19 cases (n=212), together with convalescent plasma samples collected by NHS Blood and Transplant (NHSBT) (n=462 additional samples). To determine whether PCR-positive blood samples could pose an infection risk, we attempted virus isolation from a subset of RNA-positive samples. Results: We identified 28 relevant studies, reporting SARS-CoV-2 RNA in 0-76% of blood samples; pooled estimate 10% (95%CI 5-18%). Among serum samples from our clinical cohort, 27/212 (12.7%) had SARS-CoV-2 RNA detected by RT-PCR. RNA detection occurred in samples up to day 20 post symptom onset, and was associated with more severe disease (multivariable odds ratio 7.5). Across all samples collected ≥28 days post symptom onset, 0/494 (0%, 95%CI 0-0.7%) had vRNA detected. Among our PCR-positive samples, cycle threshold (ct) values were high (range 33.5-44.8), suggesting low vRNA copy numbers. PCR-positive sera inoculated into cell culture did not produce any cytopathic effect or yield an increase in detectable SARS-CoV-2 RNA. There was a relationship between RT-PCR negativity and the presence of total SARS-CoV-2 antibody (p=0.02). Conclusions: vRNA was detectable at low viral loads in a minority of serum samples collected in acute infection, but was not associated with infectious SARS-CoV-2 (within the limitations of the assays used). This work helps to inform biosafety precautions for handling blood products from patients with current or previous COVID-19.